Sign In
Buy ANIP
$79.24
-1.19 (-1.48%)
At Close: Jul 31, 2026
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Friday, 31'st Jul 2026
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
06:50am, Friday, 24'th Jul 2026
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
09:16am, Wednesday, 22'nd Jul 2026
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande
Bessemer Group Inc. Acquires 19,800 Shares of ANI Pharmaceuticals, Inc. $ANIP
03:53am, Tuesday, 21'st Jul 2026
Bessemer Group Inc. lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 52.0% during the undefined quarter, according to its most recent disclosure with the Securities and Exc
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
04:34pm, Thursday, 16'th Jul 2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
12:55pm, Monday, 13'th Jul 2026
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results fro
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
08:46am, Monday, 13'th Jul 2026
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic...
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRON
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
08:20pm, Sunday, 12'th Jul 2026
The executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000. The transaction represented 2% of the insider's total direct equity holdings in the company.
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
05:36pm, Thursday, 09'th Jul 2026
An ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026. The sale represented 1.58% of Carey's direct holdings, reducing his direct stake to 177,543
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:46am, Thursday, 02'nd Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
10:26am, Friday, 26'th Jun 2026
ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin reve
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
10:46am, Tuesday, 16'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
02:30pm, Wednesday, 10'th Jun 2026
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
02:26pm, Wednesday, 10'th Jun 2026
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
